Pharmacological alterations of anxious behaviour in mice depending on both strain and the behavioural situation

PLoS ONE

Volumn 4, Issue 11, 2009, Pages

  Clément, Yan ^a,c   Le Guisquet, Anne Marie ^b   Venault, Patrice ^c   Chapouthier, Georges ^d   Belzung, Catherine ^b  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 5 METHOXY 3 (1,2,3,6 TETRAHYDRO 4 PYRIDYL) 1H INDOLE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; BICUCULLINE; CHLORDIAZEPOXIDE; FLUMAZENIL; SEROTONIN 1A AGONIST; SEROTONIN 1B AGONIST; 5 METHOXY 3 (1,2,3,6 TETRAHYDRO 4 PYRIDINYL)1H INDOLE; 5-METHOXY 3-(1,2,3,6-TETRAHYDRO-4-PYRIDINYL)1H INDOLE; BENZODIAZEPINE DERIVATIVE; INDOLE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CONTROLLED STUDY; DARK ADAPTATION; EXPLORATORY BEHAVIOR; FEMALE; LIGHT ADAPTATION; MALE; MAZE TEST; MOUSE; NONHUMAN; TASK PERFORMANCE; TRANQUILIZING ACTIVITY; ANIMAL; C57BL MOUSE; LIGHT; METABOLISM; PHOSPHORYLATION;

MUS;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; BENZODIAZEPINES; BICUCULLINE; CHLORDIAZEPOXIDE; FEMALE; INDOLES; LIGHT; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; PHOSPHORYLATION;

EID: 70450181390     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007745     Document Type: Article

References (86)

1. Clément Y, Chapouthier G (1998) Biological bases of anxiety. Neurosci Biobehav Rev 22: 623-633.
2. Diagnostic and statistical manual of mental disorders, 4th edition. DSM IV. (1994) American Psychiatric Association. Washington. 886 p.
3. Belzung C (1999) Rodent exploratory behavior. In: Crusio WE, Gerlai R, eds. Molecular genetic techniques for behavioral neuroscience. Elsevier: Amsterdam. pp 738-749.
4. Belzung C, Berton F (1997) Further pharmacological validation of the BALB/c neophobia in the free exploratory paradigm as an animal model of trait anxiety. Behav Pharmacol 8: 541-548.
5. Belzung C, Griebel G (2001) Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav Brain Res 125: 141-149.
6. Beuzen A, Belzung C (1995) Link between emotional memory and anxiety states: a study by principal component analysis. Physiol Behav 58: 111-118.
7. Bourin M, Petit-Demoulière B, Dhonnchadha BN, Hascöet M (2007) Animal models of anxiety in mice. Fundam Clin Pharmacol 21: 567-574.
8. Carobrez AP, Bertoglio LJ (2005) Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on. Neurosci Biobehav Rev 29: 1193-1205.
9. Carola V, D'Olimpio F, Brunamonti E, Mangia F Renzi P (2002) Evaluation of the elevated plus-maze and open-field tests for the assessment of anxiety-related behaviour in inbred mice. Behav Brain Res 134: 49-57.
10. Griebel G, Belzung C, Misslin R, Vogel E (1993) The free-exploratory paradigm: an effective method for measuring neophobic behaviour in mice and testing potential neophobia-reducing drugs. Behav Pharmacol 4: 637-644.
11. Gershenfeld HK, Paul SM (1998) Towards a genetics of anxious temperament: from mice to men. Acta Psychiatr Scand suppl 393: 56-65.
12. Lau JY, Gregory AM, Goldwin MA, Pine DS, Eley TC (2007) Assessing gene-environment interactions on anxiety symptom subtypes across childhood and adolescence. Dev Psychopathol 19: 1129-1146.
13. Clément Y, Adelbrecht C, Martin B, Chapouthier G (1994) Association of autosomal loci with the grooming activity in mice observed in open-field. Life Sci 55: 1725-1734.
14. Clément Y, Martin B, Venault P, Chapouthier G (1995) Involvement of regions of the 4th and 7th chromosomes in the open-field activity of mice. Behav Brain Res 70: 51-57.
15. Clément Y, Joubert C, Kopp C, Lepicard EM, Venault P, et al. (2007) Anxiety in mice: a principal component analysis study. Neural Plast 35457.
16. Mathis C, Neumann PE, Gershenfeld H, Paul SM, Crawley JN (1995) Genetic analysis of anxiety-related behaviors and responses to benzodiazepine-related drugs in AXB and BXA recombinant inbred mouse strains. Behav Genet 25: 557-568.
17. Rodgers RJ, Davies B, Shore R (2002) Absence of anxiolytic response to chlordiazepoxide in two common background strains exposed to the elevated plus-maze: importance and implications of behavioural baseline. Genes Brain Behav 1: 242-251.
18. Vadasz C, Kobor G, Lajtha A (1992) Motor activity and the mesotelencephalic dopamine function. I. High resolution temporal and genetic analysis of open-field behavior. Behav Brain Res 48: 29-39.
19. Van Gaalen MM, Steckler T (2000) Behavioural analysis of four mouse strains in an anxiety test battery. Behav Brain Res 115: 95-106.
20. Flint J, Corley R, DeFries JC, Fulker DW, Gray JA, et al. (1995) A simple genetic basis for a complex psychological trait in laboratory mice. Science 269: 1432-1435.
21. Talbot CJ, Nicod A, Cherny SS, Fulker DW, Collins AC, et al. (1999) High-resolution mapping of quantitative trait loci in outbred mice. Nat Genet 21: 305-308.
22. Wise J (1996) Gene may code for anxiety. Brit Med J 313: 1353.
23. Flint J, Goodwin G (1999) Psychiatric genetics: a genetic basis for health? Curr Biol 9: R326-328.
24. Clément Y, Kia KH, Daval G, Vergé D (1996) An autoradiographic study of serotonergic receptors in a murine genetic model of anxiety-related behaviors. Brain Res 709: 229-242.
25. Clément Y, Proeschel MF, Bondoux D, Girard F, Launay JM, et al. (1997) Genetic factors regulate processes related to anxiety in mice. Brain Res 752: 127-135.
26. Möhler H (2006) GABAA receptors in central nervous system disease: anxiety, epilepsy, and insomnia. J Recept Signal Transduct Res 26: 731-740.
27. Nutt D (2006) GABAA receptors: subtypes, regional distribution, and function. J Clin Sleep Med 2: S7-11.
28. Rupprecht R, Eser D, Zwanzger P, Möller HJ (2006) GABAA receptors as targets for novel anxiolytic drugs. World J Biol Psychiatry 7: 231-237.
29. Hoyer D, Clarke DE, Fozard JR Hartig PR, Martin GR, et al. (1994) VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 46: 157-203.
30. Menard J, Treit D (1999) Effects of centrally administered anxiolytic compounds in animal models of anxiety. Neurosci Biobehav Rev 23: 591-613.
31. Peroutka SJ (1994) Molecular biology of serotonin (5-HT) receptors. Synapse 18: 24-260.
32. Söderpalm B, Lundin B, Hjorth S (1993) Sustained 5-hydroxytryptamine release-inhibitory and anxiolytic-like action of the partial 5-HT1A receptor agonist, buspirone, after prolonged chronic administration. Eur J Pharmacol 239: 69-73.
33. Morelli N, Gori S, Choub A, Maluccio MR, Orlandi G, et al. (2002) Do 5HT1B/1D receptor agonists have an effect on mood and anxiety disorders? Cephalalgia 27: 471-472.
34. Wilkinson LO, Dourish CT (1991) Serotonin and animal behaviour. In: Peroutka SJ, ed. Serotonin receptor subtypes, basic and clinical aspects. New York. pp 147-210.
35. Bruening S, Oh E, Hetzenauer A, Escobar-Alvarez S, Westphalen RI, et al. (2006) The anxiety-like phenotype of 5-HT receptor null mice is associated with genetic background-specific perturbations in the prefrontal cortex GABA-glutamate system. J Neurochem 99: 892-899.
36. Crawley J, Goodwin FK (1980) Preliminary report of a single animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 13: 167-170.
37. Parks CL, Robinson PS, Sibille E, Shenk T, Toth M (1998) Increased anxiety of mice lacking the serotonin 1A receptor. Proc Natl Acad Sci USA 95: 10734-10739.
38. Ramboz S, Oosting R, Amara DA, Kung HF, Blier P, et al. (1998) Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc Natl Acad Sci USA 95: 14476-14481.
39. Rudolph U, Crestani F, Benke D, Brünig I, Benson JA, et al. (1999) Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 401: 796-80040.
40. Lesch KP (2005) Serotonergic gene inactivation in mice: models for anxiety and aggression? Novartis Found Symp 268: 111-140.
41. 1B receptor knock out - behavioral consequences. Behav Brain Res 73: 305-302.
42. Belzung C, Misslin R, Vogel E, Dodd RH, Chapouthier G (1987) Anxiogenic effects of methyl-beta-carboline-3-carboxylate in a light/dark choice situation. Pharmacol Biochem Behav 28: 29-33.
43. Lister RG (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92: 180-185.
44. Belzung C (2001) The genetic basis of the pharmacological effects of anxiolytics: a review based on rodent models. Behav Pharmacol 12: 451-460.
45. Crabbe JC, Wahlsten D, Dubek BC (1999) Genetics of mouse behavior: interactions with laboratory environment. Science 284: 1670-1672.
46. Ågmo A, Belzung C, Deloire X, Grassin M, Lewis S (1999) Blockade of anxiolytic-like actions of chlordiazepoxide by naloxone in the elevated plus-maze: Comparisons between SWISS, C57BL/6 and BALB/c mice. Psychobiology 27: 105-113.
47. Belzung C, Le Guisquet AM, Crestani F (2000) Flumazenil induces benzodiazepine partial agonist-like effects in BALB/c but not C57BL/6 mice. Psychopharmacology 148: 24-32.
48. Belzung C, Dubreuil D (1998) Naloxone potentiates the anxiolytic but not the amnesic action of chlordiazepoxide in C57BL/6 mice. Behav Pharmacol 9: 691-698.
49. Lepicard EM, Joubert C, Hagneau I, Perez-Diaz F, Chapouthier G (2000) Differences in anxiety-related behavior and response to diazepam in BALB/ cByJ and C57BL/6J strains of mice. Pharmacol Biochem Behav 67: 739-748.
50. Belzung C, Ågmo A (1997) Naloxone blocks anxiolytic-like effects of benzodiazepines in Swiss but not in Balb/c mice. Psychopharmacology 132: 195-201.
51. Bourin M, Hascoët M (2003) The mouse light/dark box test. Eur J Pharmacol 463: 55-65.
52. 1A agonist; S20244, and its enantiomers in mice. NeuroReport 3: 84-86.
53. Dolu N (2007) Dose-related anxiogenic effect of glycine in the elevated plus maze and in electrodermal activity. J Basic Clin Physiol Pharmacol 18: 141-147.
54. Florio C, Prezioso A, Papaioannou A, Vertua R (1998) Adenosine A1 receptors modulate anxiety in CD1 mice. Psychopharmacology 136: 311-319.
55. Rodgers RJ, Cole JC, Aboualfa K, Stephenson LH (1995) Ethopharmacological analysis of the effects of putative 'anxiogenic' agents in the mouse elevated plus-maze. Pharmacol Biochem Behav 52: 805-813.
56. Teixeira RM, Santos AR, Ribeiro SJ, Calixto JB, Rae GA, et al. (1996) Effects of central administration of tachykinin receptor agonists and antagonists on plusmaze behavior in mice. Eur J Pharmacol 311: 7-14.
57. Griebel G, Belzung C, Perrault G, Sanger DJ (2000) Differences in anxiety-related behaviours and in sensitivity to diazepam in inbred and outbred strains of mice. Psychopharmacology 148: 164-170.
58. Blanchard RJ, Griebel G, Henrie JA, Blanchard DC (1997) Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries. Neurosci Biobehav Rev 21: 783-789.
59. Söderpalm B, Engel JA (1990) Serotonergic involvement in conflict behaviour. Eur Neuropsychopharmacol 1: 7-13.
60. Chopin P, Briley M (1993) The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze. Psychopharmacology 110: 409-414.
61. Pellow S, File SE (1986) Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test for anxiety in the rat. Pharmacol Biochem Behav 24: 525-529.
62. Belzung C, Vogel E, Misslin R (1988) Benzodiazepine antagonist RO 15-1788 partly reverses some anxiolytic effects of ethanol in the mouse. Psychopharmacology 95: 516-519.
63. Emmanouil DE, Quock RM (1990) Effects of benzodiazepine agonist, inverse agonist and antagonist drugs in the mouse staircase test. Psychopharmacology 102: 95-97.
64. Fernández-Guasti A, Picazo O (1995) Flumazenil blocks the anxiolytic action of allopregnanolone. Eur J Pharmacol 281: 113-115.
65. Gardner CR, Budhram P (1987) Effects of agents which interact with central benzodiazepine binding sites on stress-induced ultrasounds in rat pups. Eur J Pharmacol 134: 275-283.
66. Pokk P, Zharkovsky A (1997) The effects of flumazenil, RO 15-4513 and beta-CCM on the behaviour of control and stressed mice in the plus-maze test. J Physiol Pharmacol 48: 253-261.
67. Lee C, Rodgers RJ (1991) Effects of benzodiazepine receptor antagonist, flumazenil, on antinociceptive and behavioural responses to the elevated plus-maze in mice. Neuropharmacology 30: 1263-1267.
68. File SE, Lister RG (1983) Interactions of ethyl-beta-carboline-3-carboxylate and Ro 15-1788 with CGS 8216 in an animal model of anxiety. Neurosci Lett 39: 91-94.
69. File SE, Pellow S, Jensen LH (1986) Actions of the beta-carboline ZK 93426 in an animal test of anxiety and the holeboard: interactions with RO 15-1788. J Neural Transm 65: 103-114.
70. Griebel G, Blanchard DC, Blanchard RJ (1996) Predator-elicited flight responses in Swiss-Webster mice: an experimental model of panic attacks. Prog Neuropsychopharmacol Biol Psychiatry 20: 185-205.
71. Raffali-Sébille MJ, Chapouthier G (1991) Flumazenil (Ro 15-1788) enhances learning in both negatively and positively reinforced tasks. Drug Dev Res 23: 153-157.
72. Grecksch G, Prado de Carvalho L, Venault P, Chapouthier G, Rossier J (1983) Convulsions induced by submaximal dose of pentylenetetrazol in mice are antagonized by the benzodiazepine antagonist Ro 15-1788. Life Sci 32: 2579-2584.
73. Prado de Carvalho LP, Grecksch G, Chapouthier G, Rossier J (1983) Anxiogenic and non-anxiogenic benzodiazepine antagonists. Nature 301(5895): 64-66.
74. Dantzer R, Perio A (1982) Behavioural evidence for partial agonist properties of RO 15-1788, a benzodiazepine receptor antagonist. Eur J Pharmacol 81: 655-658.
75. Ferré P, Fernández-Terruel A, Escorihuela RM, García E, Zapata A, et al. (1994) Struggling and flumazenil effects in the swimming test are related to the level of anxiety in mice. Neuropsychobiology 29: 23-27.
76. File SE, Hitchcott PK (1990) A theory of benzodiazepine dependence that can explain whether flumazenil will enhance or reverse the phenomena. Psychopharmacology 101: 525-532.
77. Griebel G (1995) 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol Ther 65: 319-395.
78. Dalvi A, Rodgers RJ (1996) GABAergic influences on plus-maze behaviour in mice. Psychopharmacology 128: 380-397.
79. Ågmo A, Pruneda R, Guzmán M, Guttiérrez M (1991) GABAergic drugs and conflict behavior in the rat: lack of similarities with the actions of benzodiazepines. Naunyn Schmiedebergs Arch Pharmacol 344: 314-322.
80. Ågmo A, Belzung C (1998) Interactions between dopamine and GABA in the control of ambulatory activity and neophobia in the mouse. Pharmacol Biochem Behav 59: 239-247.
81. Brilliant MH, Williams RW, Conti CJ, Angel JM, Oakey RJ, et al. (1994) Mouse chromosome 7. Mamm Genome 5: S104-S123.
82. Möhler H, Lusher B, Fritschy JM, Benke D, Benson J, et al. (1998) GABA(A)-receptor assembly in vivo: lessons from subunit mutant mice. Life Sci 62: 1611-1615.
83. Sánchez C (1996) 5-HT(1A) receptors play an important role in modulation of behavior of rats in a two-compartment black and white box. Behav Pharmacol 7: 788-797.
84. Griebel G, Blanchard DC, Jung A, Blanchard RJ (1995) A model of "antipredator" defense in Swiss-Webster mice: effects of benzodiazepine receptor ligands with different intrinsic activities. Behav Pharmacol 6: 732-745.
85. Pazos A, Palacios JM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res 346: 205-230.
86. Lyon MF (1989) Rules and guidelines for gene nomenclature. In: Lyon MF, Searle A, eds. Genetic variants and strains of the laboratory Mouse, Gustav Fischer Verlag, Stuttgart. pp 1-11.